Why Billionaires Are Investing in Psychedelics

t was around 5:30 a.m. and the cool, morning rains were just starting to fade and transition into the warm blanket of an orange peel sunrise. The fruit of the Staghorn Sumac was glowing and I could taste the sun-brewed Staghorn tea that I’d make this summer. I could even smell the raw, wildflower honey and sprigs of mint that I always use to liven up the extract. [Energy and Capital logo] Why Billionaires Are Investing in Psychedelics [Jeff Siegel Photo] By [Jeff Siegel]( Written May 14, 2020 I took two grams of mushrooms before heading out into the forest. It was around 5:30 a.m. and the cool, morning rains were just starting to fade and transition into the warm blanket of an orange peel sunrise. The bird songs were oddly melodic, my water jug was full, and it didn’t take long for me to start melting into my surroundings. The fruit of the Staghorn Sumac was glowing and I could taste the sun-brewed Staghorn tea that I’d make this summer. I could even smell the raw, wildflower honey and sprigs of mint that I always use to liven up the extract. If you’ve never had it before, it’s very similar to lemonade. But up here in North Country, we don’t grow lemons. And Staghorn Sumac is so hearty, it mocks the harsh winters and wet springs. I’m pretty sure that if an atom bomb landed squarely in the middle of Lake Champlain, the only thing remaining would be roaches and Staghorns. I actually thought about this quite a bit on my journey. Propped up against the withered white bark of an old Yellow Birch Tree and gazing at all the beauty God has created, I got lost in those Staghorn fruits. Hypnotized by the intricacies of their soft, fuzzy clusters and geometric shapes. And I started thinking about how this particular tree, which is littered all over the Adirondacks, is also common in the Middle East. Culturally, these worlds couldn’t be more different. Yet, here we are –– two complete universes separated by dirt, water, and politics –– but feasting upon the same fruit without any thought of physical distance or climactic diversity. Disconnected by language, culture, and war, but completely connected by nature. Not to get all treehugger on you, but that experience really made me want to share a cup of Sumac tea, with some like-minded Persians at a corner cafe in Tehran. Yes, as you can imagine it was a pleasant journey. Will This Strange “Tiny White Device” Make You 2,580% RICHER? [bbr faang holding]( It’s barely the size of a postage stamp... but for investors, it heralds the single biggest tech revolution of the 21st century. Go [HERE]( for details. But these days, magic mushrooms are no longer being sought out solely by folks like me who simply enjoy a pleasant, psychedelic experience. They’re being used to treat mental illness and with great success. Crisis Equals Opportunity Last year, you may have seen the segment that 60 Minutes produced, which focused on psychedelic medicines. During that segment, the world learned about a new treatment for smoking addiction that boasted an 86% success rate. For the sake of comparison, the most successful pharmaceutical currently on the market enjoys a 35% success rate. If “success," is what you want to call it. The fact is, this country has a very serious mental illness and drug addiction crisis. And it’s going to get worse. As reported by the Washington Post, the coronavirus pandemic is pushing America into a mental health crisis: Nearly half of Americans report the coronavirus crisis is harming their mental health, according to a Kaiser Family Foundation poll. A federal emergency hotline for people in emotional distress registered a more than 1,000 percent increase in April compared with the same time last year. Last month, roughly 20,000 people texted that hotline, run by the Substance Abuse and Mental Health Services Administration. Online therapy company Talkspace reported, a 65% jump in clients since mid-February. Text messages and transcribed therapy sessions collected anonymously by the company show coronavirus-related anxiety dominating patients’ concerns. If we don’t do something about it now, people are going to be suffering from these mental-health impacts for years to come, said Paul Gionfriddo, president of the advocacy group Mental Health America. That could further harm the economy as stress and anxiety debilitate some workers and further strain the medical system as people go to emergency rooms with panic attacks, overdoses and depression, he said. Just as the country took drastic steps to prevent hospitals from being overwhelmed by infections, experts say, it needs to brace for the coming wave of behavioral health needs. Not to sound crass, but the reality is that there’s never been a better time to bring to market, new, and potentially better treatments for mental illness. Certainly the FDA thinks so, as it has fast-tracked a number of new psychedelic medicines for clinical trials. And more are coming. This is great news for those who do suffer from mental illness and addiction. And it’s also great news for investors. You see, in addition to the hundreds of studies that suggest there are some very real benefits to treating mental illness and addiction with psychedelics… And in addition to new psychedelics decriminalization bills being introduced, debated, and yes, passed… And in addition to an overall loosening of stigmas, regarding, illegal drugs around the world… Millionaires and Billionaires Are Now Investing in Psychedelics Perhaps the most well-known is entrepreneur Peter Thiel, who happens to boast a net worth of $2.3 billion. Thiel recently ponied up big time to get a piece of ATAI Life Sciences, which is a biotech company developing psychedelic medicines for a variety of mental health issues. For Your Eyes Only Your internet speeds are about to get a revolutionary upgrade. And it'll pass thanks to a little tech firm that I almost guarantee you’ve never heard of. The new generation of internet is finally here, and I’ve figured out a way you can ride this wave for over 750% profits... But only if you get in right now. [Click here to see why your internet is about to get 20 times faster]( and to discover the little-known firm behind it that’s leading the charge. Other stinking-rich investors who have recently put up their own millions in the psychedelics space include former CEO of Canopy Growth Corporation, Bruce Linton (who amassed more than $200 million during his time with the company), and Shark Tank celebrity investor, Kevin O’Leary who boasts a net worth of about $400 million. There are more, but those are probably the most well-known and have no problem with people knowing about their investments in the psychedelics space. Others aren’t so public, and I know some of them. From elite family offices to high rollers in Silicon Valley, a lot of cash is starting to pour into this space. And when the rich folks start showing up to these parties, you know something big is about to go down. I’ll have more on this burgeoning opportunity in the coming weeks. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's [page](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [A Trade War Worth $58 Billion for Your Portfolio]( [Nothing to See Here, Move Along...]( [Elon Musk Threatens to Leave California]( [South Korea's “Digital New Deal” Prioritizes AI and 5G]( [This Coming Megatrend Will Dwarf Cannabis, Bitcoin, and 5G Combined]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.